Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
Not Applicable
Recruiting
- Conditions
- Borderline Resectable Pancreatic Cancer
- Interventions
- Procedure: Laparoscopic pancreatoduodenectomyProcedure: Open pancreatoduodenectomy
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04855331
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 224
- Registration Number
- NCT04850625
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Phase 2
- Conditions
- Cancer of Unknown Primary
- Interventions
- Drug: Recombinant humanized anti-PD-1 monoclonal antibody injection
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04848597
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04843943
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT04842565
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT04835064
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04833036
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Phase 2
Recruiting
- Conditions
- Liver Metastasis Colon Cancer
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04832776
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04831528
Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma, Gene Mutation
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04825899
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath